Resveratrol, a polyphenolic compound, has shown potential therapeutic effects against Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in in vitro and animal studies. It exhibits antisteatotic, antioxidant, and anti-inflammatory properties, inhibiting the NF-κB pathway and activating SIRT-1 and AMPK pathways. Resveratrol also normalizes the intestinal microbiome and alleviates intestinal inflammation. However, clinical trials have yielded inconclusive results regarding its efficacy in human patients. The lack of homogeneity in studies, low bioavailability of resveratrol, and differences between animal models and humans may explain these discrepancies. In vitro studies show resveratrol reduces lipid accumulation, improves mitochondrial function, and modulates lipid metabolism. Animal studies demonstrate resveratrol can improve liver histology, normalize lipid profiles, and reduce inflammation. Clinical trials have shown mixed results, with some studies indicating no significant improvement in hepatic lipid levels or liver function. Resveratrol's effects on MASLD are complex and influenced by various factors, including diet, lifestyle, and genetic predisposition. Lifestyle interventions, such as weight loss through diet and exercise, remain the primary management strategy for MASLD. The Mediterranean diet, rich in antioxidants and anti-inflammatory compounds, may also be beneficial in managing MASLD. Further research is needed to determine the efficacy of resveratrol in treating MASLD, particularly in larger clinical trials.Resveratrol, a polyphenolic compound, has shown potential therapeutic effects against Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in in vitro and animal studies. It exhibits antisteatotic, antioxidant, and anti-inflammatory properties, inhibiting the NF-κB pathway and activating SIRT-1 and AMPK pathways. Resveratrol also normalizes the intestinal microbiome and alleviates intestinal inflammation. However, clinical trials have yielded inconclusive results regarding its efficacy in human patients. The lack of homogeneity in studies, low bioavailability of resveratrol, and differences between animal models and humans may explain these discrepancies. In vitro studies show resveratrol reduces lipid accumulation, improves mitochondrial function, and modulates lipid metabolism. Animal studies demonstrate resveratrol can improve liver histology, normalize lipid profiles, and reduce inflammation. Clinical trials have shown mixed results, with some studies indicating no significant improvement in hepatic lipid levels or liver function. Resveratrol's effects on MASLD are complex and influenced by various factors, including diet, lifestyle, and genetic predisposition. Lifestyle interventions, such as weight loss through diet and exercise, remain the primary management strategy for MASLD. The Mediterranean diet, rich in antioxidants and anti-inflammatory compounds, may also be beneficial in managing MASLD. Further research is needed to determine the efficacy of resveratrol in treating MASLD, particularly in larger clinical trials.